Merck KGaA's MS Drug Mavenclad May Defy Doubters

The German group's oral treatment is late coming to the market but a key opinion leader believes that it will change the way multiple sclerosis is treated.

Man with backpack flies behind a moving train
Not too late: Merck KGaA's new MS drug can still find a place in the market • Source: Shutterstock

Now that Merck KGAA's oral multiple sclerosis drug Mavenclad (cladribine) has finally got European approval, the German group is now looking at how to make inroads into what is already a crowded market.

Mavenclad has been given the green light for the treatment of highly active relapsing MS and Merck notes that it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip